BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma

Desmoplastic infantile astrocytoma/ganglioglioma (DIA/DIG) is a rare primary neuroepithelial brain tumour typically affecting paediatric patients younger than 24 months. Knowledge about genetic alterations in DIA/DIG is limited. However, a previous study on BRAF V600E mutation in paediatric glioma revealed a BRAF mutation in one of two tested DIAs/DIGs. The limited number of cases in that study did not allow any conclusion about mutation frequency of BRAF in this tumour entity.

[1]  A. Voigt,et al.  BRAF V600E‐specific immunohistochemistry for the exclusion of Lynch syndrome in MSI‐H colorectal cancer , 2013, International journal of cancer.

[2]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[3]  L. Kristensen,et al.  A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma? , 2013, Journal of Clinical Pathology.

[4]  P. Steinbok,et al.  Malignant desmoplastic infantile astrocytoma? a case report and review of the literature. , 2013, Clinical neuropathology.

[5]  M. Preusser,et al.  Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells , 2013, Acta Neuropathologica.

[6]  N. Foreman,et al.  Brainstem ganglioglioma successfully treated with vemurafenib. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. von Deimling,et al.  Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma , 2013, The American journal of surgical pathology.

[8]  C. Horbinski.  To BRAF or Not to BRAF: Is That Even a Question Anymore? , 2013, Journal of neuropathology and experimental neurology.

[9]  W. Weichert,et al.  Application of a BRAF V600E Mutation-specific Antibody for the Diagnosis of Hairy Cell Leukemia , 2012, The American journal of surgical pathology.

[10]  A. Stenzinger,et al.  BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. , 2012, Blood.

[11]  A. Castellano-Sanchez,et al.  Strong desmin expression in a congenital desmoplastic infantile ganglioglioma mimicking pleomorphic rhadomyosarcoma: a case report including ultrastructural and cytogenetic evaluation and review of the literature , 2012, Child's Nervous System.

[12]  J. Pichler,et al.  Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases , 2012, Acta Neuropathologica.

[13]  J. Gerss,et al.  BRAF‐KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults , 2011, Neuropathology and applied neurobiology.

[14]  Barbara S. Paugh,et al.  Targeted Therapy for BRAFV600E Malignant Astrocytoma , 2011, Clinical Cancer Research.

[15]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[16]  H. Zentgraf,et al.  Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody , 2011, Acta Neuropathologica.

[17]  A. Iafrate,et al.  BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications , 2011, PloS one.

[18]  Kirsten Schmieder,et al.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.

[19]  M. Gelabert-González,et al.  Desmoplastic infantile and non-infantile ganglioglioma. Review of the literature , 2011, Neurosurgical Review.

[20]  J. Biegel,et al.  Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. , 2010, Neuro-oncology.

[21]  E. Uro-Coste,et al.  Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation , 2010, Journal of Neuro-Oncology.

[22]  B. O'neill,et al.  Gliomas in Neurofibromatosis Type 1: A Clinicopathologic Study of 100 Patients , 2008, Journal of neuropathology and experimental neurology.

[23]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[24]  M. Ruchoux,et al.  MR imaging in the diagnosis of desmoplastic infantile tumor: retrospective study of six cases. , 2004, AJNR. American journal of neuroradiology.

[25]  J. Kuratsu,et al.  Postoperative Regression of Desmoplastic Infantile Gangliogliomas: Report of Two Cases , 2003, Neurosurgery.

[26]  J. Kros,et al.  Desmoplastic infantile astrocytoma and ganglioglioma: a search for genomic characteristics , 2002, Acta Neuropathologica.

[27]  B. Scheithauer,et al.  Mixed Conventional and Desmoplastic Infantile Ganglioglioma: an Autopsied Case with 6-Year Follow-Up , 2001, Modern Pathology.

[28]  S. Vandenberg.  Desmoplastic Infantile Ganglioglioma and Desmoplastic Cerebral Astrocytoma of Infancy , 1993, Brain pathology.

[29]  D. Louis,et al.  Desmoplastic cerebral astrocytomas of infancy: a histopathologic, immunohistochemical, ultrastructural, and molecular genetic study. , 1992, Human pathology.

[30]  A. Taratuto,et al.  Intracranial neoplasms during the first year of life. , 1986, Surgical neurology.

[31]  Barbara S. Paugh,et al.  Targeted Therapy for Braf V600e Malignant Astrocytoma Statement of Translational Relevance , 2022 .